AC Immune SA
No enriched coverage for $ACIU in the last 7 days.
No SEC Form 4 filings for $ACIU in the last 30 days.
See all $ACIU insider activity →Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
AC Immune (ACIU) reported positive interim Phase 1 data for ACI-19764, an oral NLRP3 inhibitor. The therapy was safe, well-tolerated, and showed dose-dependent inhibition of IL-1beta. Initial results from a cardiovascular risk cohort are expected by year-end. ACIU stock is down 4.07% to $2.47.
AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.
Recent ACIU coverage spans technology, earnings and regulation.
Early‑stage data de‑risk the program and attract further capital.
Positive early‑stage data may lift near‑term sentiment and support a short‑term price rally.
Positive safety and pharmacokinetic data may boost investor confidence and support near‑term price appreciation.
Regulatory acceleration plus interim safety data increases probability of near-term clinical progress and can extend the valuation runway for ACI-7104.
Fast Track status can accelerate development and regulatory interactions for ACI-7104, supporting a more favorable path toward later trial readouts.
AlphAI scores every news story that mentions ACIU with an AI model for sentiment and relevance, and aggregates insider trades from AC Immune SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
3 min readAC Immune (ACIU) reported positive interim Phase 1 data for ACI-19764, an oral NLRP3 inhibitor. The therapy was safe, well-tolerated, and showed dose-dependent inhibition of IL-1beta. Initial results from a cardiovascular risk cohort are expected by year-end. ACIU stock is down 4.07% to $2.47.
2 min readAC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.
2 min readAC Immune (ACIU) shares rose 3.4% pre-open after the FDA granted Fast Track status to its ACI-7104 anti-alpha-synuclein therapy and cleared its IND. The move allows Phase 2 VacSYn trial enrollment to expand to U.S. sites. Interim 76-week Part 1 data showed a favorable safety profile. The stock was near $2.37.
4 min readAC Immune SA (ACIU) said the FDA granted Fast Track designation to its ACI-7104 anti-alpha-synuclein immunotherapy for early Parkinson’s. The drug is in the VacSYn Phase 2 trial; Part 1 interim data at 76 weeks reported safety and a 100% immunogenicity responder rate. Next steps include U.S. site expansion after IND clearance and week-100 results in H2 2026.
4 min readAC Immune SA (ACIU) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments ● Key advances across pipeline, with further near-term
2 min readAC Immune SA (NASDAQ: ACIU) reported a half-year update for June 30, 2026, highlighting Phase 2 VacSYn Part 1 full results for ACI-7104 in H2 2026, Phase 1/1b data for ACI-19764 in H2 2026, and Phase 1 PET results for ACI-19626. Cash was CHF 75.4m. Revenues were CHF 16.2m. A $12m Takeda milestone was triggered for ACI-24.
6 min readAC Immune SA (NASDAQ: ACIU) said it will present three neurodegenerative disease pipeline updates at AAIC 2026 in London (July 12–15). It plans to share early human imaging for the [18F]ACI-19626 TDP-43 PET tracer, Phase 1 data for NLRP3 inhibitor ACI-19764, and preclinical results for an alpha-synuclein aggregation inhibitor.
2 min readAC Immune SA (NASDAQ: ACIU) reported interim 12-month Phase 1b/2 ABATE trial data for ACI-24 in 74 prodromal Alzheimer’s patients across AD1–AD3 cohorts. Company said ACI-24 was generally safe and well tolerated with no ARIA-E and anti–Abeta antibodies detected at all dose levels with a dose response. AD4 is ongoing with an added adjuvant; Takeda has an option/license agreement.
4 min readAC Immune SA (NASDAQ: ACIU) said it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its Phase 2 VacSYn trial of ACI-7104 in early Parkinson’s disease by 2 years to assess long-term safety and efficacy. Final Part 1 results (to week 104) are expected in H2 2026.
4 min read
